The authors reply

New England Journal of Medicine

Volumn 369, Issue 5, 2013, Pages 488-489

  Swedberg, Karl ^a   McMurray, John J V ^b   Young, James B ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; IRON DEFICIENCY; IRON DEPLETION; IRON THERAPY; LETTER; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTOLIC HEART FAILURE; FEMALE; MALE; NOTE;

ANEMIA; ERYTHROPOIETIN; FEMALE; HEART FAILURE, SYSTOLIC; HEMATINICS; HUMANS; MALE;

EID: 84880859687     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1306321     Document Type: Letter

References (1)

1. van Veldhuisen DJ, McMurray JJ. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 2007;9:110-2. [Erratum, Eur J Heart Fail 2007;9:323.] (Pubitemid 46394086)